Perlegen Sciences Licenses Late-Stage Compound From Mitsubishi Pharma

Perlegen Sciences and Mitsubishi Pharma have announced a licensing agreement for the late-stage development and commercialization of MCC-555 (a peroxisome proliferator activated receptor (PPAR) agonist) for the treatment of diabetes and other metabolic disorders.

Perlegen intends to apply its leading whole genome pharmacogenomics technology to improve upon the demonstrated efficacy and safety profile of MCC-555, which has been tested in more than 1,000 patients. By guiding treatment to patients most likely to benefit, the companies expect this "personalization" of the drug to provide superior therapeutic benefit in an area of significant medical need.